INTRODUCTION {#s1}
============

Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome or infantile periarteritis nodosa, inflames the walls of both small- and medium-sized blood vessels (vasculitis), particularly coronary arteries, throughout the body. KD typically affects children under the age of five years \[[@R1]\]. The most serious cardiovascular complications of KD are the result of coronary artery lesions (CALs) caused by inflammation, including myocardial infarctions, coronary artery fistula formations \[[@R2]\], coronary artery dilatations, and coronary artery aneurysms (CAAs) \[[@R3]\]. Although this disease can be controlled, nearly 20% of children who do not receive treatment suffer a CAA \[[@R2]\], which may lead to death in severe cases.

Matrix metalloproteinases (MMPs) may maintain the structure and function of coronary vascular walls \[[@R4]\]. MMP-9 and -7 are well known to influence CAA formation in KD \[[@R5], [@R6]\]. Shimizu *et al.* reported that haplotype analyses showed MMP-3 and -12 in the gene cluster on Chromosome 11 in CAA formation in KD patients \[[@R7]\]. The proinflammatory cytokine tumor necrosis factor-α (TNF-α) that stimulates MMP-9 production was also correlated with vascular damage in a KD model \[[@R8]\].

Epigenetics describes the acetylation pattern of the genome and DNA methylation and subsequently leads to changes in the chromatin structure \[[@R9]\]. In short, DNA methylation can deactivate genes through DNA methyltransferases \[[@R10]\]. In contrast, demethylation alterations of CpG sites indicate a contradictory change in gene expression \[[@R11]\]. In previous studies, we found that IVIG treatment significantly altered methylation patterns in KD patients \[[@R12]\] and that KD patients demonstrated considerably increased mRNA expression in TLRs and hypomethylation at the gene promoters of TLRs \[[@R13]\]. IVIG treatment can restore the methylation level of TLRs and decrease these TLRs' mRNA expression \[[@R13]\]. No studies have yet surveyed all the MMP-1∼28 in the same report or performed analysis with methylation profiles. Therefore, in this study, we comprehensively examined the mRNA expressions of MMPs-1∼28 and analyzed changes in methylation levels in two different stages of KD patients, as well as two types of controls.

RESULTS {#s2}
=======

Differential expression of MMP mRNA levels among KD patients and controls and changes after IVIG treatment {#s2_1}
----------------------------------------------------------------------------------------------------------

To investigate MMP1-28 transcripts expression, we used Affymetrix GeneChip^®^ Human Transcriptome Array 2.0 to determine their expression levels. Table [1](#T1){ref-type="table"} shows that KD patients had a differential expression of MMPs when compared to both the healthy and febrile control subjects. The mRNA levels of MMP-8, -9, and -25 were significantly higher in KD patients than in the healthy control and febrile control groups. These values significantly decreased in KD patients after undergoing IVIG treatment (Figure [1](#F1){ref-type="fig"}). We observed no noteworthy differences in the remaining MMPs among the groups or in KD patients following IVIG treatment.

###### Transcripts expressions of matrix metalloproteinases (MMPs) between Kawasaki disease patients and control subjects

  Symbol   RefSeq         Fold-Change   *p* value   Fold-Change   *p* value   Fold-Change   *p* value
  -------- -------------- ------------- ----------- ------------- ----------- ------------- -----------
  MMP1     NM_001145938   1.067         0.267       -1.046        0.425       -1.053        0.366
  MMP2     NM_001127891   -1.004        0.970       -1.005        0.960       1.092         0.363
  MMP3     NM_002422      1.009         0.865       -1.085        0.163       1.014         0.803
  MMP7     NM_002423      1.011         0.876       -1.038        0.582       -1.001        0.990
  MMP8     NM_002424      7.143         0.001\*     2.176         0.083       -7.587        0.001\*
  MMP9     NM_004994      4.062         0.000\*     1.771         0.037\*     -4.481        0.000\*
  MMP10    NM_002425      -1.008        0.888       -1.104        0.093       1.020         0.709
  MMP11    NM_005940      -1.024        0.825       -1.042        0.709       1.097         0.407
  MMP12    NM_002426      1.050         0.389       -1.046        0.427       -1.013        0.814
  MMP13    NM_002427      1.008         0.859       -1.100        0.060       1.029         0.531
  MMP14    NM_004995      1.072         0.449       -1.059        0.531       1.029         0.756
  MMP15    NM_002428      -1.023        0.817       -1.056        0.588       1.064         0.537
  MMP16    NM_005941      1.007         0.928       -1.115        0.171       1.049         0.528
  MMP17    NM_016155      -1.024        0.797       -1.086        0.388       1.035         0.717
  MMP19    NM_002429      1.055         0.580       -1.017        0.864       -1.001        0.988
  MMP20    NM_004771      -1.014        0.789       -1.093        0.111       1.026         0.620
  MMP21    NM_147191      -1.036        0.546       -1.034        0.567       1.059         0.336
  MMP23B   NM_006983      -1.060        0.580       -1.070        0.527       1.084         0.449
  MMP24    NM_006690      -1.014        0.904       -1.027        0.822       1.052         0.669
  MMP25    NM_022468      1.859         0.013\*     1.473         0.082       -1.915        0.010\*
  MMP26    NM_021801      -1.030        0.619       -1.093        0.157       1.069         0.272
  MMP27    NM_022122      1.000         0.999       -1.047        0.438       1.055         0.369
  MMP28    NM_001032278   1.011         0.914       -1.015        0.877       1.029         0.767

KD1: Kawasaki disease before IVIG treatment; KD3: Kawasaki disease \> 3 weeks after IVIG treatment; FC: febrile control; HC: healthy control.

![Comparison of matrix metalloproteinase (MMP) -8, -9, and -25 mRNA expressions by GeneChip^®^ Human Transcriptome Array 2.0 between acute-stage Kawasaki disease patients and control subjects\
\* indicates significance (*p* \< 0.05). Data are expressed as mean ± standard error for the three replications.](oncotarget-08-60875-g001){#F1}

Significantly altered CpG sites on MMPs between KD patients and controls {#s2_2}
------------------------------------------------------------------------

We adopted Illumina HumanMethylation450 BeadChip (Illumina) to assess the methylation patterns of CpG sites on MMPs between KD patients and both types of control subjects (Table [2a](#T2a){ref-type="table"}-[2g](#T2g){ref-type="table"}). The MMP methylation levels were found to vary considerably in the acute stage of KD patients compared to the healthy and febrile controls (Table [2a](#T2a){ref-type="table"}-[2g](#T2g){ref-type="table"}). Furthermore, the methylation levels of MMP1-28 were significantly lower in acute-stage KD patients compared to the healthy and febrile controls (Table [2a](#T2a){ref-type="table"}-[2g](#T2g){ref-type="table"}). After KD patients underwent IVIG treatment, the methylation status of MMP-2, -9, -14, -15, and -16 was significantly increased, while the remaining MMPs were significantly decreased (Table [2a](#T2a){ref-type="table"}-[2g](#T2g){ref-type="table"}). Decreased methylation results in greater gene expression \[[@R12]\], so we focused on the correlation between DNA methylation patterns and gene expressions. As shown in Figure [2](#F2){ref-type="fig"}, MMP-9 demonstrates a hypo-methylated status in KD patients not yet treated with IVIG compared to the control subjects and the KD patients already treated with IVIG. Therefore, the mRNA expression level and DNA methylation of MMP-9 represent a negative correlation, thus indicating that DNA methylation can repress gene expression.

###### Methylation patterns of CpG sites on matrix metallo proteinase between Kawasaki disease patients and control subjects

  Target ID    Symbol   Fold-Change   *p*-value   Fold-Change   *p*-value   Fold-Change   *p*-value
  ------------ -------- ------------- ----------- ------------- ----------- ------------- -----------
  cg02212280   MMP1     -1.005        0.086       1.010         0.003\*     -1.046        0.000\*
  cg11531628            -1.001        0.652       -1.003        0.206       1.005         0.029\*
  cg13759446            -1.001        0.002\*     1.005         0.089       -1.017        0.000\*
  cg14543953            -1.003        0.629       1.004         0.529       -1.070        0.000\*
  cg16575408            -1.002        0.488       1.002         0.408       -1.014        0.000\*
  cg18733315            -1.012        0.000\*     -1.001        0.708       -1.003        0.389
  cg00078334   MMP2     -1.022        0.000\*     -1.018        0.000\*     1.019         0.000\*
  cg00087906            1.001         0.463       -1.001        0.276       1.005         0.000\*
  cg01821058            -1.003        0.071       -1.004        0.041\*     1.007         0.000\*
  cg02458945            -1.003        0.028\*     1.004         0.004\*     -1.003        0.009\*
  cg07582157            -1.010        0.003\*     -1.010        0.003\*     1.041         0.000\*
  cg08318842            -1.010        0.000\*     -1.010        0.000\*     1.015         0.000\*
  cg09530163            -1.009        0.003\*     -1.009        0.002\*     1.002         0.520
  cg10079740            -1.003        0.015\*     1.003         0.012\*     -1.001        0.238
  cg12317456            -1.011        0.000\*     -1.007        0.012\*     1.004         0.129
  cg14400118            -1.007        0.012\*     -1.014        0.000\*     1.006         0.047\*
  cg22950163            -1.010        0.000\*     -1.015        0.000\*     1.013         0.000\*
  cg25029998            -1.011        0.263       -1.003        0.793       -1.008        0.408
  cg25349472            -1.004        0.715       1.002         0.850       1.003         0.780
  cg26795346            -1.007        0.024\*     1.002         0.568       -1.018        0.000\*
  cg27016988            -1.010        0.016\*     -1.001        0.893       1.011         0.011\*
  cg27279620            -1.004        0.371       -1.016        0.000\*     1.024         0.000\*
  cg27642062            -1.001        0.433       -1.005        0.004\*     1.006         0.003\*
  cg01027553   MMP3     -1.007        0.089       -1.007        0.120       1.006         0.133
  cg03168922            -1.008        0.185       -1.002        0.786       -1.015        0.009\*
  cg03231596            -1.019        0.008\*     -1.009        0.209       1.009         0.215
  cg16466334            -1.009        0.017\*     -1.010        0.007\*     -1.014        0.000\*
  cg17145397            -1.010        0.015\*     1.002         0.613       -1.012        0.007\*
  cg18113270            -1.003        0.319       1.000         0.875       -1.016        0.000\*
  cg01813071   MMP7     -1.023        0.000\*     -1.009        0.098       1.053         0.000\*
  cg04059146            -1.010        0.020\*     1.002         0.650       -1.045        0.000\*
  cg17707274            -1.047        0.000\*     -1.043        0.000\*     1.096         0.000\*
  cg20645973            -1.028        0.000\*     -1.013        0.011\*     -1.007        0.140
  cg24963041            -1.002        0.516       1.007         0.063       -1.025        0.000\*
  cg25511807            -1.137        0.000\*     -1.064        0.001\*     1.053         0.005\*
  cg01092036   MMP8     -1.011        0.000\*     1.004         0.180       -1.015        0.000\*
  cg00182727   MMP9     -1.025        0.000\*     -1.026        0.000\*     1.017         0.000\*
  cg00732815            -1.047        0.000\*     -1.031        0.000\*     1.046         0.000\*
  cg02310296            -1.044        0.000\*     -1.029        0.000\*     1.025         0.000\*
  cg08176368            1.004         0.127       1.010         0.001\*     -1.024        0.000\*

###### Methylation patterns of CpG sites on matrix metallo proteinase between Kawasaki disease patients and control subjects

  Target ID    Symbol   Fold-Change   *p*-value   Fold-Change   *p*-value   Fold-Change   *p*-value
  ------------ -------- ------------- ----------- ------------- ----------- ------------- -----------
  cg10505873   MMP9     -1.091        0.000\*     -1.057        0.000\*     1.064         0.000\*
  cg20925811            -1.049        0.000\*     -1.050        0.000\*     1.025         0.039\*
  cg21451869            -1.024        0.000\*     -1.029        0.000\*     1.020         0.001\*
  cg23353432            -1.006        0.022\*     -1.011        0.000\*     1.012         0.000\*
  cg26132320            -1.019        0.025\*     -1.008        0.295       -1.030        0.000\*
  cg27372994            -1.023        0.003\*     -1.011        0.159       1.007         0.385
  cg15259031   MMP10    -1.011        0.006\*     -1.004        0.294       -1.004        0.332
  cg24960563            -1.001        0.490       -1.001        0.314       1.002         0.189
  cg00771653   MMP11    -1.019        0.002\*     1.002         0.744       -1.046        0.000\*
  cg03207310            -1.005        0.009\*     1.000         0.798       1.004         0.032\*
  cg03290040            -1.005        0.023\*     -1.008        0.000\*     1.019         0.000\*
  cg04058144            -1.001        0.335       -1.003        0.054       1.004         0.002\*
  cg08141518            -1.026        0.147       1.000         0.993       -1.045        0.015\*
  cg09133003            -1.005        0.476       -1.002        0.779       -1.023        0.004\*
  cg12256538            -1.014        0.000\*     -1.013        0.000\*     1.037         0.000\*
  cg12395479            -1.008        0.033\*     -1.014        0.000\*     1.003         0.372
  cg13361393            1.013         0.002\*     1.017         0.000\*     -1.029        0.000\*
  cg15808568            -1.007        0.759       1.041         0.065       -1.018        0.412
  cg16159491            -1.002        0.228       -1.004        0.044 \*    1.010         0.000\*
  cg18240463            1.003         0.695       -1.002        0.771       -1.015        0.025\*
  cg19934709            -1.002        0.419       1.011         0.000\*     -1.012        0.000\*
  cg20202552            -1.009        0.000\*     -1.000        0.973       -1.007        0.002\*
  cg21776003            1.007         0.009\*     -1.002        0.452       -1.006        0.029\*
  cg23261640            1.008         0.260       1.021         0.004\*     -1.002        0.763
  cg23327483            1.004         0.028\*     1.010         0.000\*     -1.006        0.001\*
  cg27532722            -1.030        0.000\*     -1.009        0.173       1.031         0.000\*
  cg02368591   MMP12    -1.015        0.021\*     1.011         0.070       -1.031        0.000\*
  cg09002726            -1.020        0.001\*     1.004         0.503       -1.014        0.017\*
  cg14948108            -1.008        0.038\*     1.007         0.078       -1.023        0.000\*
  cg19304432            -1.005        0.128       1.006         0.060       -1.022        0.000\*
  cg20487452            -1.019        0.012\*     1.001         0.925       -1.020        0.008\*
  cg23979520            -1.010        0.183       1.002         0.775       -1.039        0.000\*
  cg03067994   MMP13    -1.009        0.005\*     1.001         0.689       -1.037        0.000\*
  cg10085326            -1.007        0.439       1.005         0.526       -1.067        0.000\*
  cg13041032            -1.001        0.663       1.006         0.004\*     -1.027        0.000\*
  cg14995062            -1.007        0.216       1.009         0.086       -1.032        0.000\*
  cg16919569            -1.018        0.028\*     -1.008        0.293       -1.000        0.997
  cg19620758            1.012         0.203       1.019         0.045\*     -1.049        0.000\*
  cg22658979            -1.006        0.042\*     -1.001        0.792       -1.007        0.010\*
  cg24301681            -1.016        0.001\*     -1.009        0.031\*     -1.018        0.000\*

###### Methylation patterns of CpG sites on matrix metallo proteinase between Kawasaki disease patients and control subjects

  Target ID    Symbol   Fold-Change   *p*-value   Fold-Change   *p*-value   Fold-Change   *p*-value
  ------------ -------- ------------- ----------- ------------- ----------- ------------- -----------
  cg00691240   MMP14    -1.009        0.571       1.012         0.421       -1.038        0.015\*
  cg01016847            -1.051        0.000\*     -1.026        0.001\*     1.035         0.000\*
  cg01508380            -1.078        0.000\*     -1.049        0.002\*     1.027         0.070
  cg04556361            -1.001        0.885       1.012         0.009\*     -1.045        0.000\*
  cg05931439            -1.061        0.000\*     -1.033        0.005\*     1.024         0.042\*
  cg08321366            -1.077        0.000\*     -1.059        0.000\*     1.023         0.039\*
  cg09208010            -1.140        0.000\*     -1.085        0.000\*     1.070         0.001\*
  cg10418289            -1.081        0.000\*     -1.057        0.000\*     1.090         0.000\*
  cg10599444            -1.067        0.000\*     -1.044        0.000\*     1.037         0.001\*
  cg13094752            -1.085        0.000\*     -1.049        0.001\*     1.007         0.594
  cg16119835            -1.019        0.000\*     -1.012        0.020\*     1.014         0.005\*
  cg18525873            -1.004        0.436       1.005         0.331       1.002         0.638
  cg25594542            -1.015        0.000\*     -1.003        0.384       -1.012        0.000\*
  cg27020028            -1.006        0.078       1.006         0.123       -1.008        0.030\*
  cg00247629   MMP15    -1.009        0.127       -1.001        0.887       -1.008        0.170
  cg00963305            1.002         0.095       -1.004        0.000\*     1.004         0.000\*
  cg01812337            -1.007        0.348       -1.011        0.147       1.056         0.000\*
  cg04211309            -1.016        0.000\*     -1.002        0.491       -1.013        0.000\*
  cg05910755            -1.000        0.963       1.009         0.000\*     -1.005        0.000\*
  cg06649282            -1.022        0.000\*     -1.010        0.021\*     -1.022        0.000\*
  cg06856889            -1.008        0.003\*     -1.000        0.878       1.006         0.026\*
  cg08082374            -1.006        0.193       1.016         0.001\*     1.028         0.000\*
  cg08514765            -1.011        0.000\*     -1.005        0.017\*     -1.000        0.927
  cg08552042            -1.007        0.068       1.013         0.001\*     -1.000        0.945
  cg08877948            -1.005        0.215       -1.009        0.037\*     1.026         0.000\*
  cg08943809            1.003         0.214       1.016         0.000\*     -1.017        0.000\*
  cg10396713            -1.043        0.001\*     -1.022        0.085       1.004         0.747
  cg16181803            1.000         0.955       -1.009        0.000\*     1.006         0.001\*
  cg16652241            1.001         0.616       -1.005        0.018\*     1.008         0.000\*
  cg18333626            -1.001        0.793       -1.004        0.451       1.011         0.040\*
  cg18442019            -1.009        0.041\*     -1.006        0.141       1.007         0.100
  cg20566643            -1.006        0.001\*     -1.010        0.000\*     1.013         0.000\*
  cg20751926            -1.020        0.013\*     -1.022        0.008\*     -1.005        0.524
  cg24306779            -1.001        0.811       -1.011        0.000\*     1.004         0.154
  cg25449950            1.015         0.095       -1.002        0.856       1.004         0.657
  cg26725183            -1.003        0.335       1.017         0.000\*     1.011         0.001\*
  cg26919014            -1.018        0.000\*     -1.004        0.225       -1.004        0.233
  cg27208052            -1.033        0.000\*     -1.006        0.448       1.019         0.017\*
  cg00021786   MMP16    -1.009        0.169       -1.008        0.210       1.011         0.105
  cg02889488            1.001         0.796       1.026         0.000\*     -1.018        0.000\*

###### Methylation patterns of CpG sites on matrix metallo proteinase between Kawasaki disease patients and control subjects

  Target ID    Symbol   Fold-Change   *p*-value   Fold-Change   *p*-value   Fold-Change   *p*-value
  ------------ -------- ------------- ----------- ------------- ----------- ------------- -----------
  cg03210866   MMP16    -1.019        0.277       1.013         0.437       -1.030        0.090
  cg04684553            1.016         0.018\*     1.008         0.205       1.070         0.000\*
  cg05033271            1.006         0.383       1.000         0.981       1.107         0.000\*
  cg07609388            -1.006        0.029\*     -1.026        0.000\*     1.019         0.000\*
  cg08624180            -1.007        0.050\*     -1.011        0.003\*     1.018         0.000\*
  cg11536457            -1.001        0.685       1.000         0.935       1.025         0.000\*
  cg14644752            1.001         0.781       1.015         0.000\*     1.033         0.000\*
  cg16852892            -1.007        0.005\*     -1.006        0.032\*     1.010         0.000\*
  cg22405982            -1.004        0.078       1.002         0.460       -1.001        0.470
  cg24403959            -1.003        0.544       -1.010        0.082       -1.002        0.763
  cg24456365            -1.006        0.112       -1.004        0.266       -1.011        0.008\*
  cg26075830            -1.021        0.000\*     -1.008        0.059       1.003         0.442
  cg02309230   MMP17    1.016         0.109       1.032         0.002\*     1.003         0.756
  cg02714882            -1.002        0.097       1.002         0.055       -1.002        0.065
  cg03064145            -1.004        0.048\*     -1.011        0.000\*     1.007         0.003\*
  cg04346459            -1.036        0.045\*     -1.002        0.907       1.028         0.114
  cg07699454            -1.022        0.016\*     1.001         0.863       1.016         0.067
  cg10105149            -1.008        0.037\*     -1.007        0.065       -1.004        0.308
  cg10673839            1.003         0.487       1.003         0.468       -1.015        0.000\*
  cg11510557            1.000         0.720       1.009         0.000\*     -1.010        0.000\*
  cg13082201            -1.002        0.229       -1.006        0.002\*     1.009         0.000\*
  cg14215776            1.001         0.131       -1.003        0.000\*     1.006         0.000\*
  cg15454599            -1.006        0.004\*     -1.006        0.002\*     1.006         0.005\*
  cg20393882            -1.007        0.248       1.009         0.147       -1.000        0.981
  cg20844545            -1.000        0.838       -1.005        0.001\*     1.004         0.009\*
  cg23477406            -1.001        0.563       -1.004        0.000\*     1.004         0.000\*
  cg24493940            -1.003        0.550       1.000         0.930       -1.021        0.000\*
  cg25531700            -1.004        0.060       -1.009        0.000\*     1.014         0.000\*
  cg26326372            -1.021        0.153       -1.032        0.031\*     1.020         0.172
  cg26356412            -1.019        0.002\*     -1.016        0.009\*     1.023         0.000\*
  cg26569074            -1.009        0.001\*     -1.017        0.000\*     -1.004        0.133
  cg27207041            1.001         0.657       1.006         0.005\*     -1.002        0.391
  cg27305698            -1.006        0.045\*     1.002         0.559       -1.008        0.006\*
  cg03509949   MMP19    -1.160        0.000\*     -1.096        0.000\*     1.126         0.000\*
  cg09907201            -1.023        0.001\*     -1.018        0.008\*     -1.029        0.000\*
  cg16936370            -1.021        0.015\*     -1.019        0.022\*     1.030         0.001\*
  cg17865265            -1.124        0.000\*     -1.068        0.000\*     1.074         0.000\*
  cg18787783            -1.005        0.201       1.004         0.322       -1.036        0.000\*
  cg25006073            -1.010        0.116       1.003         0.615       -1.095        0.000\*
  cg10553219   MMP20    -1.007        0.684       1.043         0.028\*     -1.020        0.284

###### Methylation patterns of CpG sites on matrix metallo proteinase between Kawasaki disease patients and control subjects

  Target ID    Symbol   Fold-Change   *p*-value   Fold-Change   *p*-value   Fold-Change   *p*-value
  ------------ -------- ------------- ----------- ------------- ----------- ------------- -----------
  cg12020179   MMP20    -1.003        0.505       1.021         0.000\*     -1.047        0.000\*
  cg23275776            1.001         0.889       -1.005        0.247       -1.076        0.000\*
  cg26757793            -1.004        0.386       1.011         0.018\*     -1.025        0.000\*
  cg02964396   MMP21    1.002         0.142       1.001         0.628       1.001         0.586
  cg03437479            -1.020        0.007\*     -1.006        0.359       1.011         0.120
  cg03553576            -1.019        0.066       -1.011        0.276       -1.006        0.567
  cg04358037            -1.009        0.006\*     -1.004        0.240       -1.010        0.002\*
  cg05670995            -1.041        0.015\*     -1.040        0.018\*     -1.015        0.346
  cg05721877            1.053         0.236       1.039         0.386       -1.096        0.039\*
  cg07954108            -1.008        0.018\*     -1.012        0.001\*     -1.006        0.084
  cg09540803            -1.001        0.603       -1.003        0.257       -1.019        0.000\*
  cg11240212            -1.001        0.336       -1.003        0.035\*     1.003         0.088
  cg11254426            -1.011        0.044\*     1.001         0.861       -1.017        0.003\*
  cg12666819            -1.004        0.100       -1.003        0.313       1.002         0.395
  cg12854248            -1.015        0.000\*     -1.008        0.010\*     1.000         0.960
  cg24307114            -1.011        0.001\*     -1.013        0.000\*     1.019         0.000\*
  cg24383498            -1.001        0.825       1.004         0.552       -1.023        0.000\*
  cg25400200            -1.013        0.044\*     -1.012        0.060       -1.026        0.000\*
  cg25906360            -1.013        0.059       -1.006        0.349       -1.032        0.000\*
  cg26907302            -1.009        0.005\*     -1.003        0.388       -1.007        0.030\*
  cg00262621   MMP23A   1.021         0.002\*     1.010         0.130       -1.031        0.000\*
  cg00297832            1.029         0.005\*     1.028         0.007\*     -1.003        0.729
  cg00341415            -1.014        0.012\*     -1.004        0.435       -1.016        0.005\*
  cg00369151            1.004         0.807       -1.005        0.769       -1.025        0.179
  cg01154903            -1.009        0.224       -1.007        0.332       -1.017        0.028\*
  cg02519897            1.002         0.705       1.001         0.818       1.018         0.003\*
  cg02599583            -1.006        0.762       1.022         0.267       -1.044        0.035\*
  cg03001942            -1.011        0.020\*     -1.006        0.182       1.008         0.092
  cg03136646            -1.029        0.000\*     -1.018        0.001\*     1.021         0.000\*
  cg03427058            1.011         0.512       1.051         0.003\*     -1.083        0.000\*
  cg03930970            -1.005        0.076       1.000         0.892       -1.002        0.387
  cg04437922            -1.011        0.102       1.001         0.864       -1.054        0.000\*
  cg04882394            -1.000        0.986       -1.012        0.000\*     1.014         0.000\*
  cg05642789            1.011         0.561       1.060         0.003\*     -1.072        0.000\*
  cg06084034            -1.107        0.012\*     -1.040        0.318       1.019         0.639
  cg06750152            -1.009        0.024\*     1.007         0.073       -1.012        0.006\*
  cg09937190            -1.105        0.001\*     -1.066        0.036\*     1.038         0.217
  cg11648594            1.019         0.007\*     1.015         0.032\*     -1.028        0.000\*
  cg12534645            1.025         0.042\*     1.017         0.161       1.016         0.191
  cg17402325            -1.016        0.009\*     -1.017        0.005\*     1.008         0.186

###### Methylation patterns of CpG sites on matrix metallo proteinase between Kawasaki disease patients and control subjects

  Target ID    Symbol   Fold-Change   *p*-value   Fold-Change   *p*-value   Fold-Change   *p*-value
  ------------ -------- ------------- ----------- ------------- ----------- ------------- -----------
  cg18852096   MMP23A   -1.010        0.475       1.003         0.840       -1.051        0.000\*
  cg21265770            -1.018        0.027\*     1.002         0.812       -1.034        0.000\*
  cg23125449            -1.009        0.013\*     -1.003        0.464       1.011         0.006\*
  cg24688574            -1.001        0.724       1.005         0.140       -1.032        0.000\*
  cg27474382            1.013         0.219       1.017         0.113       -1.011        0.277
  cg00262621   MMP23B   1.021         0.002\*     1.010         0.130       -1.031        0.000\*
  cg00297832            1.029         0.005\*     1.028         0.007\*     -1.003        0.729
  cg00369151            1.004         0.807       -1.005        0.769       -1.025        0.179
  cg01154903            -1.009        0.224       -1.007        0.332       -1.017        0.028\*
  cg02599583            -1.006        0.762       1.022         0.267       -1.044        0.035\*
  cg03001942            -1.011        0.020\*     -1.006        0.182       1.008         0.092
  cg03136646            -1.029        0.000\*     -1.018        0.001\*     1.021         0.000\*
  cg03427058            1.011         0.512       1.051         0.003\*     -1.083        0.000\*
  cg03930970            -1.005        0.076       1.000         0.892       -1.002        0.387
  cg04854189            -1.008        0.030\*     -1.003        0.348       -1.020        0.000\*
  cg04882394            -1.000        0.986       -1.012        0.000\*     1.014         0.000\*
  cg05642789            1.011         0.561       1.060         0.003\*     -1.072        0.000\*
  cg06080300            -1.068        0.000\*     -1.043        0.000\*     1.026         0.010\*
  cg06084034            -1.107        0.012\*     -1.040        0.318       1.019         0.639
  cg06912282            -1.115        0.000\*     -1.059        0.000\*     1.076         0.000\*
  cg09937190            -1.105        0.001\*     -1.066        0.036\*     1.038         0.217
  cg11648594            1.019         0.007\*     1.015         0.032\*     -1.028        0.000\*
  cg12534645            1.025         0.042\*     1.017         0.161       1.016         0.191
  cg17402325            -1.016        0.009\*     -1.017        0.005\*     1.008         0.186
  cg18852096            -1.010        0.475       1.003         0.840       -1.051        0.000\*
  cg23125449            -1.009        0.013\*     -1.003        0.464       1.011         0.006\*
  cg02288791   MMP24    -1.005        0.280       1.003         0.421       -1.035        0.000\*
  cg03260792            1.000         0.806       -1.002        0.252       1.001         0.522
  cg04316754            -1.013        0.056       1.001         0.832       1.046         0.000\*
  cg12483876            -1.003        0.676       -1.007        0.289       1.056         0.000\*
  cg15270813            -1.017        0.088       -1.005        0.610       1.039         0.000\*
  cg00456894   MMP25    1.000         0.838       1.004         0.000\*     1.000         0.716
  cg01270736            -1.021        0.002\*     -1.026        0.000\*     1.005         0.448
  cg02616220            -1.005        0.231       1.011         0.008\*     -1.048        0.000\*
  cg02988422            -1.014        0.123       -1.013        0.152       1.009         0.325
  cg05168200            1.004         0.330       1.020         0.000\*     -1.030        0.000\*
  cg06697694            1.003         0.172       1.002         0.264       1.020         0.000\*
  cg08607821            -1.008        0.095       -1.005        0.280       -1.005        0.285
  cg10620273            1.001         0.654       1.007         0.001\*     -1.004        0.040\*
  cg16856286            -1.002        0.437       -1.004        0.211       1.008         0.016\*

###### Methylation patterns of CpG sites on matrix metallo proteinase between Kawasaki disease patients and control subjects

  Target ID    Symbol   Fold-Change   *p*-value   Fold-Change   *p*-value   Fold-Change   *p*-value
  ------------ -------- ------------- ----------- ------------- ----------- ------------- -----------
  cg19612376   MMP25    -1.004        0.237       1.001         0.789       -1.003        0.295
  cg22053861            -1.004        0.061       -1.002        0.255       -1.001        0.490
  cg23531828            1.002         0.867       -1.012        0.181       -1.014        0.125
  cg25584355            1.001         0.585       -1.005        0.008\*     1.001         0.496
  cg26705553            -1.006        0.001\*     1.009         0.000\*     -1.003        0.172
  cg26942943            -1.006        0.006\*     -1.002        0.444       1.010         0.000\*
  cg02706104   MMP26    -1.005        0.147       1.000         0.990       -1.038        0.000\*
  cg05316601            -1.013        0.000\*     -1.003        0.334       -1.030        0.000\*
  cg09805271            -1.013        0.176       -1.009        0.335       -1.104        0.000\*
  cg12493906            -1.028        0.000\*     -1.008        0.143       1.017         0.002\*
  cg17992177            -1.018        0.001\*     -1.006        0.261       -1.032        0.000\*
  cg23389785            -1.009        0.015\*     -1.006        0.108       1.000         0.943
  cg06259570   MMP27    -1.012        0.012\*     -1.011        0.019\*     -1.037        0.000\*
  cg09758894            -1.011        0.015\*     1.008         0.082       -1.015        0.001\*
  cg13252516            1.003         0.329       1.006         0.080       -1.038        0.000\*
  cg18932968            -1.003        0.302       1.013         0.000\*     -1.025        0.000\*
  cg25277638            -1.024        0.039\*     -1.009        0.456       1.004         0.730
  cg01134296   MMP28    -1.024        0.000\*     -1.019        0.000\*     1.020         0.000\*
  cg01352921            -1.001        0.304       -1.002        0.201       1.004         0.001\*
  cg01622018            -1.062        0.000\*     -1.022        0.046\*     1.018         0.091
  cg04790749            -1.004        0.614       1.009         0.273       -1.063        0.000\*
  cg07330075            -1.005        0.184       1.009         0.021\*     -1.029        0.000\*
  cg07546558            1.009         0.002\*     1.008         0.003\*     -1.011        0.000\*
  cg07916589            -1.005        0.231       1.006         0.164       1.004         0.378
  cg09357580            1.004         0.004\*     1.003         0.031\*     -1.003        0.018\*
  cg09730211            1.003         0.143       1.007         0.003\*     -1.014        0.000\*
  cg09807148            -1.014        0.000\*     -1.002        0.444       -1.002        0.501
  cg12700449            -1.028        0.000\*     -1.017        0.001\*     -1.001        0.893
  cg13326172            1.001         0.460       -1.005        0.001\*     1.005         0.001\*
  cg16246294            1.002         0.486       1.014         0.000\*     -1.015        0.000\*
  cg25172682            1.018         0.095       1.009         0.415       -1.042        0.000\*

For simplicity, we listed the p values only to 10-3. Actually, the CpG marker cg10505873 (the target for further examination) has p value \< 10-5 among all of the three comparisons (KD1 vs. FC, KD1 vs. HC and KD3 vs. KD1). When examined with the FDR (with Bonferroni correction), cg10505873 is also significant among the three comparisons.

KD1: Kawasaki disease before IVIG treatment; KD3: Kawasaki disease \> 3 weeks after IVIG treatment; FC: febrile control; HC: healthy control.

![Integration of CpG marker (cg10505873) methylation pattern and gene expression profile of matrix metalloproteinase (MMP)-9\
**a**. The methylation patterns of the representative CpG marker and gene expression profile of MMP-9 showed negative tendencies and were observed to change in both the healthy and febrile control subjects, as well as KD patients before and after receiving intravenous immunoglobulin treatment. The histogram and curve are presented as mean ± standard error. **b**. We used scatter plots to demonstrate the correlations between mRNA levels and DNA methylation, which show that mRNA levels were negatively correlated with DNA methylation (Pearson's correlation coefficient approximately -0.603 and *p* \< 0.001).](oncotarget-08-60875-g002){#F2}

MMP-8, -9 and -25 expressions in peripheral white blood cells (WBCs) of KD patients and controls {#s2_3}
------------------------------------------------------------------------------------------------

We examined the mRNA levels of MMP-8, -9, and -25 in a separate cohort consisting of 31 KD patients and 46 controls (23 healthy and 23 febrile controls) using real-time PCR. We found higher MMP-8 (*p* =0.004), MMP-9 (*p* =0.024), and MMP-25 mRNA levels (*p* = 0.002) in the WBCs of KD patients than in those of the controls, as shown in Figure [3](#F3){ref-type="fig"}. Such findings are consistent with the Affymetrix GeneChip^®^ Human Transcriptome Array 2.0 results. Moreover, the mRNA level of MMP-9 was greater in KD patients who developed CAL than those who did not (*p* = 0.035) (Figure [4](#F4){ref-type="fig"}).

![Analyses of matrix metalloproteinase (MMP) -8, -9, and -25 mRNA in the peripheral blood mononuclear cells of 31 patients with KD and 46 controls using a real-time quantitative polymerase chain reaction\
Data are expressed as mean ±standard error. \*indicates a p \< 0.05 between the groups.](oncotarget-08-60875-g003){#F3}

![Comparison of matrix metalloproteinase 9 in patients with KD without (*n* = 22) and with (*n* = 9) coronary artery lesion before being treated with intravenous immunoglobulin\
Data are presented as mean ±standard error. \*indicates a *p* \< 0.05 between the groups.](oncotarget-08-60875-g004){#F4}

DISCUSSION {#s3}
==========

To the best of our knowledge, ours is the first study to comprehensively survey global DNA methylation levels and transcripts of MMPs between KD patients and control subjects. Our noteworthy observations include the epigenetic hypomethylation and upregulation of MMP-9 in KD, as well as the increase of mRNA levels of MMP-9 in KD patients with CAL formation.

Cardiovascular complications are the leading cause of morbidity and mortality in KD patients \[[@R14]\]. Coronary dilatation followed by aneurysm occurs in 20-25% of KD children who do not receive treatment \[[@R15], [@R16]\]. Undergoing IVIG treatment can effectively decrease the likelihood of CAA formation, but its effect on etiology aneurysm formation remains unclear \[[@R14], [@R17]\]. An increasing amount of evidence has also suggested that children with KD are at a long-term risk for subsequent cardiovascular events, possibly due to the endothelial dysfunction and inflammation of the coronary and systemic arteries \[[@R18], [@R19]\]. MMPs have an important controlling influence regarding maintaining coronary vascular wall structure and function \[[@R4]\]. Previous studies have reported a significant correlation between MMP-9 with coronary artery disease \[[@R20]\] and outcomes after acute myocardial infarction \[[@R21]\]. The overexpression of MMP-2, -8, -9, and -12 was related to abdominal aortic aneurysm \[[@R22]\]. Likewise, MMP-8, -9, and -12 seem to be associated with collagen I and collagen III, as well as their degradation products and vascular remodeling \[[@R22]\]. More importantly, Newby *et al.* proposed that MMP-mediated macrophage invasion and tissue destruction fosters the ideal environment for atherosclerotic plaque rupture \[[@R23]\].

While increasing evidence has indicated that cytokine profiles are related to the pathogenesis of KD, the actual CALs involved remain unclear. MMP-3 and -12 haplotypes have been correlated with CAA formation in patients with KD \[[@R7]\], while MMP-11 polymorphism may be correlated with KD in Korean children \[[@R24]\]. Furthermore, diffuse and strong staining of MMP-9 was observed in coronary lesions of children who died from KD \[[@R25]\], as was an increased MMP-9 expression in vascular endothelial cells induced by the serum of KD patients \[[@R26]\]. Remarkably, MMP-9 activity can aid in breaking down elastin \[[@R27]\], so hampering such activity can improve coronary artery inflammation in a KD animal model \[[@R28]\]. IVIG treatment can also inhibit monocytes that express MMP-9, thus decreasing chemotactic migration of monocytes and CAL development \[[@R29]\]. was Another study showed that treatment with TNF-α \[[@R30]\] and advanced glycation end products decrease the promoter DNA methylation and increase the endogenous expression of MMP-9 in the human keratinocyte cell line \[[@R31]\]. Moreover, oxidized low-density lipoprotein significantly increased primary human aortic smooth muscle cell migration by decreasing DNA methylation levels and increasing MMP-9 expression \[[@R32]\], which supports our finding that expression abundance of MMP-9 can be altered and negatively correlated with the methylation profile. In our previous studies, we have described KD patients showing remarkably increased mRNA expression in TLRs and hypomethylation at TLR gene promoters \[[@R13]\]. Interestingly, Soria-Valles at al. showed that MMP-25 could activate the innate immune response \[[@R33]\]. Similarly, our study has also found increased transcripts of MMP-8, MMP-9, and MMP-25 in KD, indicating that these proteinases may be potential therapeutic targets for KD.

Prostaglandin E2 (PGE2) is a prostanoid created by almost all vascular cell types and takes part in vascular wall remodeling by regulating MMP activities \[[@R34]\]. PGE2 can further stimulate MMP-9 expression in inflammatory cells \[[@R35]\], and we discovered that plasma PGE2 is correlated with the prevention of IVIG resistance and CAL formation through CD40L in KD \[[@R36]\]. A previous study found that transcripts correlated with MMP-9 and interferon-gamma in PBMC in patients with coronary artery ectasia \[[@R37]\], while we observed an association among IFNG gene polymorphisms, susceptibility to KD, IVIG responsiveness, and plasma IFN-γ levels in KD patients \[[@R38]\]. In this study, we demonstrated that MMP-9 was not only upregulated in KD but also had a significant correlation with CAL formation in Taiwanese KD patients. These observations provide insight into the association among inflammatory cytokines, matrix metalloproteinases, and CAL formation in KD. As a result, we may use MMP gene expression and DNA methylation as KD biomarkers to develop an effective KD diagnosis model.

This study has various limitations. First, we do not know if potential changes in methylation occur due to an association with decreased inflammation or due to the IVIG treatment. Second, we use total WBCs in this study, but determining whether specific types of blood cells, such as regulatory T cells, or specific markers show epigenetic changes with IVIG or KD would be productive and interesting.

CONCLUSIONS {#s4}
===========

Our report is the first to observe DNA hypomethylation, an increased MMP-9 transcript in KD compared to controls and an upregulation of MMP-9 in KD patients with CAL formation.

MATERIALS AND METHODS {#s5}
=====================

Patients {#s5_1}
--------

For this study, we recruited a total of 54 subjects from Kaohsiung Chang Gung Memorial Children's Hospital in Taiwan in this study. Of those, 18 subjects were fever controls (with fever but not diagnosed to have KD), 18 subjects were healthy controls (with a history of neither fever nor KD), and the remaining 18 subjects were KD patients who had had samples collected both before and after IVIG treatment, met the American Heart Association diagnosis criteria, which is characterized by prolonged fever for more than five days, conjunctivitis, diffuse mucosal inflammation, polymorphous skin rashes, indurative edema of the hands and feet associated with peeling of the finger tips, and non-suppurative lymphadenopathy \[[@R39], [@R40]\], and received IVIG treatment at the hospital. Using a separate cohort, we performed real-time quantitative PCR validations of mRNA levels in 31 KD patients, 23 healthy controls, and 23 febrile controls. The patients in the fever control group had diagnoses of acute tonsillitis, croup, acute bronchitis, or urinary tract infection. We took peripheral blood samples from KD patients at two points: prior to being treated with IVIG (pre-IVIG) and at least three weeks after completing IVIG treatment (37.8 ± 4.0 days), as described in our previous studies \[[@R36]\]. A CAL was defined as a coronary artery with an internal diameter of at least 3 mm (4 mm if the subject was older than 5 years) or a segment with an internal diameter at least 1.5 times larger than that of an adjacent segment, as observed through echocardiography \[[@R14], [@R41]\]. This study received approval from the Chang Gung Memorial Hospital's Institutional Review Board (IRB No.:101-4618A3), and we obtained written informed consent from the parents or guardians of all subjects. All of the methods used comply with the relevant guidelines established.

Experiment design {#s5_2}
-----------------

First, we collected whole blood samples from the subjects and subjected said samples to WBC enrichment, as described in a previous study \[[@R12]\]. The enriched WBC samples were then subjected to either RNA or DNA extraction. We used an isolation kit (mirVana™ miRNA Isolation Kit, Catalog number: AM1560, Life Technologies, Carlsbad, CA) following the manufacturer's instructions to isolate total RNA and measured the collected RNA samples using Bioanalyzer (ABI) and Qubit (Thermo) to calculate both the quality (RIN value) and quantity of the RNA. All RNA samples passed the criterion of RIN≧7. We isolated the DNA samples and treated them with bisulfite as previously described in another study \[[@R42]\].

Gene expression profiling with microarray {#s5_3}
-----------------------------------------

For strong, unbiased results, pooled RNA libraries were created by evenly pooling six RNA samples, which resulted in three pooled normal control, three fever control, three pre-IVIG, and three post-IVIG libraries. We submitted the pooled RNA samples to microarray assay to establish the gene expression profiles. We further performed profiling with GeneChip^®^ Human Transcriptome Array 2.0 (HTA 2.0, Affymetrix, Santa Clara). We used the WT PLUS Reagent kit to prepare the RNA samples and then performed hybridization on the HTA 2.0 microarray chips. In accordance with the Affymetrix instruction manual, the raw data of the HTA 2.0 chips underwent quality control examination, as previously described \[[@R13]\].

DNA methylation profiling with Illumina M450K BeadChip {#s5_4}
------------------------------------------------------

We used Illumina HumanMethylation450 (M450K) BeadChip to perform genome-wide screening of DNA methylation patterns. The M450K BeadChip program was created to detect methylation patterns of approximately 450,000 CpG markers, thus spanning the entire human genome. Additional information about M450 BeadChip can be found at the following website: <http://support.illumina.com/array/array_kits/infinium_humanmethylation450_beadchip_kit.html>. For each M450K BeadChip assay, we applied 200 ng of bisulfite-converted genomic DNA in accordance with the manufacturer's instructions, as previously described \[[@R12]\]. Then, we calculated the methylation percentage of cytosine for each CpG marker in each sample, referring to them as β values.

RNA isolation and real-time quantitative RT-PCR {#s5_5}
-----------------------------------------------

In order to quantify the mRNA levels of MMP-8, -9, and -25, we performed real-time quantitative PCR using the ABI 7700 Sequence Detection System (TaqMan; Applied Biosystems, Inc., Foster City, CA). We separated the total mRNA from the WBC using an isolation kit (mirVana™ miRNA Isolation Kit, Catalog number: AM1560, Life Technologies, Carlsbad, CA), following the manufacturer's instructions. We performed PCR using a SYBR Green PCR Master Mix containing 10 μM of specific forward and reverse primers. The relative quantification of gene expression was carried out based on the comparative threshold cycle (C~T~) method, through which the target amount was determined to be 2^−(ΔCT\ target\ −\ Δ\ CT\ calibrator)^ or 2^−ΔΔCT^ \[[@R43]\]. Primers were designed to amplify the target genes, which are provided in Table [4](#T4){ref-type="table"}. We performed all experiments twice for verification and to validate the amplification efficiencies.

###### Basal characteristics of controls and patients with KD

  Characteristic         Healthy controls   Febrile controls   Patients with KD
  ---------------------- ------------------ ------------------ ------------------
  Male gender, n (%)     26(63.4)           25(60.9)           34(69.3)
  Mean (± SD), age (y)   6.1 ± 4.7          3.3 ± 2.6          1.8 ± 1.7
  CAL formation                                                18(36.7%)

CAL, coronary artery lesion; KD, Kawasaki disease; SD, standard deviation

###### Primers were designed to amplify target genes

  Gene symbol   Accession number   Hybridization   Primers (5' to 3')        Primer location   Amplicon size (bp)
  ------------- ------------------ --------------- ------------------------- ----------------- --------------------
  RNA18S5       NR_003286.2        forward         GTAACCCGTTGAACCCCATT      1577 - 1597       151
                                   reverse         CCATCCAATCGGTAGTAGCG      1708 - 1727       
  MMP8          NM_002424          forward         TTGGGTTGAATGTGACGG        308 -- 326        156
                                   reverse         GTATAGTTTCGAATCCTGTAGGT   439 - 463         
  MMP9          NM_004994          forward         TCCAACCACCACCACAC         1378 -- 1396      178
                                   reverse         CGGACTCAAAGGCACAGTA       1534 -- 1555      
  MMP25         NM_022468          forward         GGACACTCACTTTGACGAT       852 -- 873        192
                                   reverse         GAGACAGGCGGTACTTG         1026 - 1043       

Statistical analysis {#s5_6}
--------------------

We have presented all data as mean ± standard error. The chips that passed the quality control criteria were analyzed with Partek (Partek, St. Louis), commercial software designed specifically to analyze microarray data. Using Partek, we conducted ANOVA analysis and reported the p-values of the comparisons of interest as previously described \[[@R13]\].

We applied Student's t-test or one-way ANOVA, as appropriate, to analyze the quantitative data. Furthermore, we evaluated any data changes before and after IVIG treatment with the paired sample *t-*test. All statistical analyses were carried out using SPSS version 22.0 for Windows XP (SPSS, Inc., Chicago, USA), and a two-sided p-value less than 0.05 was considered statistically significant.
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